About Cobalamin binding intrinsic factor
Cobalamin binding intrinsic factor (CBLIF) is a protein
from Homo sapiens identified by UniProt accession
P27352, 417 residues long.
MolForge cross-references it against 0 known binders and
301 disease associations.
Target properties
| Protein name | Cobalamin binding intrinsic factor |
| UniProt accession | P27352 |
| Gene | CBLIF |
| Organism | Homo sapiens |
| Length | 417 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (301)
Diseases linked to this target (Open Targets).
- Congenital intrinsic factor deficiency · score 0.68
- hereditary intrinsic factor deficiency · score 0.64
- Gräsbeck-Imerslund disease · score 0.37
- gastric carcinoma · score 0.05
- sex hormone-binding globulin measurement · score 0.05
- body height · score 0.05
- dehydrated hereditary stomatocytosis · score 0.05
- vitamin B12 measurement · score 0.05
- Hemolytic anemia due to red cell pyruvate kinase deficiency · score 0.05
- infection · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P27352-F1 | alphafold | PREDICTED | 90.51 | — |
Amino-acid sequence (417 residues)
MAWFALYLLS LLWATAGTST QTQSSCSVPS AQEPLVNGIQ VLMENSVTSS AYPNPSILIA MNLAGAYNLK AQKLLTYQLM SSDNNDLTIG QLGLTIMALT SSCRDPGDKV SILQRQMENW APSSPNAEAS AFYGPSLAIL ALCQKNSEAT LPIAVRFAKT LLANSSPFNV DTGAMATLAL TCMYNKIPVG SEEGYRSLFG QVLKDIVEKI SMKIKDNGII GDIYSTGLAM QALSVTPEPS KKEWNCKKTT DMILNEIKQG KFHNPMSIAQ ILPSLKGKTY LDVPQVTCSP DHEVQPTLPS NPGPGPTSAS NITVIYTINN QLRGVELLFN ETINVSVKSG SVLLVVLEEA QRKNPMFKFE TTMTSWGLVV SSINNIAENV NHKTYWQFLS GVTPLNEGVA DYIPFNHEHI TANFTQY
Explore Cobalamin binding intrinsic factor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets